IRCT20200513047423N5
Completed
未知
Bioequivalance study of Famotidine 40 mg tablets manufactured by Fatak Chemie pars pharmaceutical company on 24 healthy volunteers and comparing pharmacokinetics results with famotidine tablets manufactured by Ratiopharm.
Fatak chemie pars Pharmacy0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fatak chemie pars Pharmacy
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy liver
- •Healthy kidney
- •Volunteers should not be too fat or too thin and their weight index should be in the appropriate range
Exclusion Criteria
- •Out of age ranges
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Bioequivalance study of Famotidine 40 mgSubject: Bioequivalence of Famotidine 40 mg Tablet and Comparison of Pharmacokinetic Parameters with Ratiopham Reference Tablet.IRCT20200513047423N9Iran Daru Pharmaceutical Company24
Not yet recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mgIRCT20200623047902N14Sanamed pharma company24
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20200105046010N85Tabriz University of Medical Sciences24
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20210519051345N32Tabriz University of Medical Sciences24
Recruiting
Not Applicable
Bioequivalence study of famotidine 40 mg tabletIRCT20230222057495N12Ramopharmin Pharmaceutical Company24